Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313012 · ClinicalTrials.gov registry record · Phase 1
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02313012 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 19 participants.
The verdict
NCT02313012, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
Interventions
- DRUG CC-90003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-01-05 |
| Est. Completion | 2016-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313012
The ClinicalTrials.gov registry entry for NCT02313012 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-90003 is the first listed.
NCT02313012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313012 about?
NCT02313012 is a clinical study titled "Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors". The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
What is the current status of trial NCT02313012?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2015-01-05. Estimated completion is 2016-05-03.
What interventions are being tested in trial NCT02313012?
The interventions under investigation include: CC-90003 (DRUG).
Who is sponsoring clinical trial NCT02313012?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.